ReviewGeroScience2026
Molecular predictors of incident frailty: a systematic review and critical appraisal of longitudinal evidence.
Review in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Frailty is a multisystemic syndrome that significantly compromises quality of life. Current management strategies are largely reactive, often leading to suboptimal mitigation outcomes. Identifying predictors of incident frailty is therefore critical to shift this paradigm. This systematic review conducted in PubMed, Scopus and Web of Science (on 3 October 2023) included 45 longitudinal studies analysing biomarkers in human biological fluids and their associations with widely established frailty assessment tools. A total of 80 candidate biomarkers were identified, 20 of which were investigated in multiple studies. Notably, only one biomarker analysed in multiple studies was found to have broadly similar directionality in adjusted analyses, but overall certainty remains limited. While our findings suggest that some progress has been made towards the discovery of molecular predictors of incident frailty, a reliable biomarker set remains elusive, hindered by several methodological limitations. Nevertheless, frailty assessment has shown tremendous promise in the clinical setting, warranting further efforts to integrate existing tools with biomarkers. This systematic review highlights the untapped potential of biomarker discovery, as well as the current shortcomings in the field of frailty prediction, and offers direction for improving study design and reproducibility in future studies.
Indexed as
Identifiers
42174345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.